Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 9/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19873904 | 1.00 | GNRHR (0.36) | GNRHRCYP3A4DHODHMALT1UTS2R | |
| SCHEMBL28644183 | 0.92 | GNRHR (0.35) | GNRHRCYP3A4DHODHMALT1UTS2R | |
| SCHEMBL28644185 | 0.92 | GNRHR (0.35) | GNRHRCYP3A4DHODHMALT1UTS2R | |
| SCHEMBL30178450 | 0.89 | GNRHR (0.34) | GNRHRCYP3A4DHODHMALT1UTS2R | |
| SCHEMBL19873887 | 0.89 | GNRHR (0.34) | GNRHRCYP3A4DHODHMALT1UTS2R | |
| SCHEMBL19873888 | 0.89 | GNRHR (0.34) | GNRHRCYP3A4DHODHMALT1UTS2R | |
| SCHEMBL30178412 | 0.89 | P2RX3 (0.34) | P2RX3KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL30178348 | 0.82 | GNRHR (0.41) | GNRHRCYP3A4MALT1SCN9A | |
| SCHEMBL17870723 | 0.82 | GNRHR (0.41) | GNRHRCYP3A4MALT1SCN9A | |
| SCHEMBL19873791 | 0.82 | GNRHR (0.39) | GNRHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708566-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2023-02-08 | — | — | EP | disclosed |
| CN-107428744-B | Novel heterocyclic compounds and their use in medicine and cosmetics | 盖尔德马研究及发展公司 | 2021-09-24 | — | — | CN | disclosed |
| EP-3708566-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2020-09-16 | — | — | EP | disclosed |
| EP-3237403-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2020-05-06 | — | — | EP | disclosed |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-02-22 | — | — | US | disclosed |
| EP-3237403-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102882-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | MC1R, CALCRL, BDKRB2 | GNRHR 215/4885CYP3A4 2314/4885DHODH 749/4885 |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | MC1R, BDKRB2, CCKBR | GNRHR 201/4885CYP3A4 1806/4885DHODH 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.